Doxorubicin ITC complaint
Executive Summary
Erbamont withdraws motion for a temporary exclusion order against Bristol-Myers and Cetus, filed with the company's complaint to the International Trade Commission in May. On Nov. 6, an administrative law judge will hear arguments for a permanent exclusion order against the importation of doxorubicin into the U.S. Bristol and Cetus began selling doxorubicin products in the U.S. in May upon the expiration of Erbamont's product patent for doxorubicin (Adriamycin). The complaint alleges that the two companies infringe Erbamont's process patent, which expires in 1991.